BACKGROUND: Metastatic colorectal cancer is frequently treated with irinotecan, a topoisomerase-I inhibitor. The UGT1A1 gene encodes for an enzyme that metabolizes irinotecan, and its genetic variants were shown to be associated with increased drug toxicity. We evaluated clinical outcomes associated with the UGT1A1*28 variant. METHODS: The study included 329 colorectal cancer patients from the Israeli population-based Molecular Epidemiology of Colorectal Cancer study who were treated with a chemotherapy regimen that included irinotecan. Patients with metastases or disease recurrence were followed up for a median period of 2 years after occurrence of the event. Study end points were appearance of grade 3-4 hematological and gastroenterological toxicity, hospitalization due to toxic events (mostly neutropenia, fever, diarrhea, or vomiting), length of hospitalization, and overall survival. UGT1A1*28 was genotyped from peripheral blood DNA by fragment analysis and reported as number of TATA sequence repeats in the promoter of the gene. RESULTS: The 7/7 variant of UGT1A1*28 was detected in 11.9% of the 329 participants. Grade 3-4 hematological toxicity was significantly higher in 7/7 carriers compared with 6/7 and 6/6 carriers (48.0%,10.2%, and 7.7% respectively; P < .001), as was the risk of toxicity-related hospitalization (45.8%, 25.3%, and 14.4% respectively; P = .001). Both short-term death within 2 months of treatment start (12.8%, 5.2%, and 2.9%, respectively) and median overall survival (1.6, 2.0, and 2.4 years, respectively; P = .01) were significantly worse in the 7/7 carriers. The age/stage-adjusted hazard ratio for patients with the 7/7 genotype compared with 6/6 was 1.7 (95% confidence interval, 1.1-2.3). CONCLUSIONS: The UGT1A1*28 7/7 genotype is strongly associated with severe hematological toxicity and higher hospitalization rate and predicts lower survival of colorectal cancer in users of irinotecan.
BACKGROUND: Metastatic colorectal cancer is frequently treated with irinotecan, a topoisomerase-I inhibitor. The UGT1A1 gene encodes for an enzyme that metabolizes irinotecan, and its genetic variants were shown to be associated with increased drug toxicity. We evaluated clinical outcomes associated with the UGT1A1*28 variant. METHODS: The study included 329 colorectal cancerpatients from the Israeli population-based Molecular Epidemiology of Colorectal Cancer study who were treated with a chemotherapy regimen that included irinotecan. Patients with metastases or disease recurrence were followed up for a median period of 2 years after occurrence of the event. Study end points were appearance of grade 3-4 hematological and gastroenterological toxicity, hospitalization due to toxic events (mostly neutropenia, fever, diarrhea, or vomiting), length of hospitalization, and overall survival. UGT1A1*28 was genotyped from peripheral blood DNA by fragment analysis and reported as number of TATA sequence repeats in the promoter of the gene. RESULTS: The 7/7 variant of UGT1A1*28 was detected in 11.9% of the 329 participants. Grade 3-4 hematological toxicity was significantly higher in 7/7 carriers compared with 6/7 and 6/6 carriers (48.0%,10.2%, and 7.7% respectively; P < .001), as was the risk of toxicity-related hospitalization (45.8%, 25.3%, and 14.4% respectively; P = .001). Both short-term death within 2 months of treatment start (12.8%, 5.2%, and 2.9%, respectively) and median overall survival (1.6, 2.0, and 2.4 years, respectively; P = .01) were significantly worse in the 7/7 carriers. The age/stage-adjusted hazard ratio for patients with the 7/7 genotype compared with 6/6 was 1.7 (95% confidence interval, 1.1-2.3). CONCLUSIONS: The UGT1A1*28 7/7 genotype is strongly associated with severe hematological toxicity and higher hospitalization rate and predicts lower survival of colorectal cancer in users of irinotecan.
Authors: Floris A de Jong; Diederik F S Kehrer; Ron H J Mathijssen; Geert-Jan Creemers; Peter de Bruijn; Ron H N van Schaik; André S Th Planting; Ate van der Gaast; Ferry A L M Eskens; Jos Th P Janssen; Jan B Ruit; Jaap Verweij; Alex Sparreboom; Maja J A de Jonge Journal: Oncologist Date: 2006-09
Authors: Katrin E Rhodes; Wu Zhang; Dongyun Yang; Oliver A Press; Michael Gordon; Daniel Vallböhmer; Anne M Schultheis; Georg Lurje; Robert D Ladner; William Fazzone; Syma Iqbal; Heinz-Josef Lenz Journal: Drug Metab Lett Date: 2007-01
Authors: Roberta Ferraldeschi; Laura J Minchell; Stephen A Roberts; Simon Tobi; Kristen D Hadfield; Fiona H Blackhall; Saifee Mullamitha; Gregory Wilson; Juan Valle; Mark Saunders; William G Newman Journal: Pharmacogenomics Date: 2009-05 Impact factor: 2.533
Authors: Janelle M Hoskins; Richard M Goldberg; Pingping Qu; Joseph G Ibrahim; Howard L McLeod Journal: J Natl Cancer Inst Date: 2007-08-28 Impact factor: 13.506
Authors: E Rouits; V Charasson; A Pétain; M Boisdron-Celle; J-P Delord; M Fonck; A Laurand; A-L Poirier; A Morel; E Chatelut; J Robert; E Gamelin Journal: Br J Cancer Date: 2008-09-16 Impact factor: 7.640
Authors: Juan Daniel Díaz-García; Angel Gallegos-Villalobos; Liliana Gonzalez-Espinoza; Maria D Sanchez-Niño; Jesus Villarrubia; Alberto Ortiz Journal: Nat Rev Nephrol Date: 2014-07-22 Impact factor: 28.314
Authors: Gustaw Lech; Robert Słotwiński; Maciej Słodkowski; Ireneusz Wojciech Krasnodębski Journal: World J Gastroenterol Date: 2016-02-07 Impact factor: 5.742